$3,210.31 travel Payment -- Takeda Pharmaceuticals to Dr. Richard Brown

Rare Disease Specialist Dr. Richard Brown Receives Travel Payment from Takeda Pharmaceuticals

This page provides a detailed analysis of a $3,210.31 travel payment from Takeda Pharmaceuticals to Dr. Richard Brown. Data is from the CMS Open Payments (Sunshine Act) database.

Payment Details

Field	Value
Amount	$3,210.31
Payment Type	travel
Payment Nature	Travel and Lodging
Pharmaceutical Company	Takeda Pharmaceuticals
Physician	Dr. Richard Brown
NPI Number	1514008786
Physician Specialty	Rare Disease
Location	City, CO
Date of Payment	2025-02-15
Conflict Assessment	Moderate -- Worth Noting

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Takeda Pharmaceuticals made a $3.2K travel payment to Richard Brown, a Rare Disease specialist in City, CO. Dr. Richard Brown received $3,210.31 from Takeda Pharmaceuticals for travel and lodging on February 15, 2025. The payment was associated with the 'Rare Disease' specialty. This payment falls under the 'travel' payment type.

Patient Guidance: What This Payment Means for You

This payment was for travel and lodging expenses related to your medical practice. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Payments for travel and lodging to rare disease specialists can vary, but this amount should be reviewed in the context of typical industry practices for similar educational or consulting activities.

Regulatory Context: Sunshine Act Requirements

This payment is reported under the CMS Open Payments program, which requires disclosure of financial relationships between drug and device manufacturers and physicians.

Understanding travel Payments

Travel and lodging payments cover transportation and accommodation expenses for physicians attending conferences, advisory board meetings, or speaking engagements sponsored by pharmaceutical companies. These payments can be substantial, particularly for international travel or multi-day events.

Frequently Asked Questions About This Payment

What was this $3.2K payment for?

This was a travel payment of $3.2K from Takeda Pharmaceuticals to Richard Brown, categorized as "Travel and Lodging". The payment was reported under the Sunshine Act (CMS Open Payments).

Does Richard Brown accept pharmaceutical money?

Yes, Richard Brown received this $3.2K payment from Takeda Pharmaceuticals. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Richard Brown's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this travel payment?

A travel payment of $3.2K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Rare Disease?

To compare this payment against Rare Disease averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Rare Disease physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Richard Brown's relationship with Takeda Pharmaceuticals?

The payment amount is $3,210.31. This $3.2K travel payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Rare Disease?

The payment was made by Takeda Pharmaceuticals.

What should patients do after learning about this payment?

This payment was for travel and lodging expenses related to your medical practice.

What else should I know about this travel payment?

The date of payment was February 15, 2025.

Related Reports

Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.